Reader’s guide · First edition · September 2026 · Revised October 1, 2026
GLOW
A guide to the three-peptide blend vial: a skin peptide injected in bulk, two healing peptides along for the ride, and no study of any of it together
GLOW is a research-vendor product, not a molecule: 50 mg of GHK-Cu, 10 mg of BPC-157, and 10 mg of TB-500 freeze-dried together in one 70 mg vial and sold for skin, hair, and healing at once. KLOW adds 10 mg of KPV for inflammation. The three ingredients have three different evidence records, none of them for injection, and the combination has never been studied by anyone. This guide takes the vial apart: what each ingredient is, what the dose arithmetic does to each of them, why a fixed-ratio blend is the wrong way to take peptides even if you believe in the peptides, and where every one of them stands with the FDA.
Who this is for
Written for adults who are using, or being offered, the GLOW or KLOW blend for skin, hair, recovery, or inflammation. It summarizes the published record for each ingredient and the regulatory position as of the edition date. It is not medical advice.
The name is marketing and the composition is convention: vendors converged on the same recipe because it packages three of their best sellers into one purchase. Every vendor's GLOW has the same three peptides in the same proportions; the only choice is whether to add KPV and call it KLOW.
| Ingredient | Amount | Share of the powder | What it is sold for |
|---|---|---|---|
| GHK-Cu | 50 mg | 71% | Skin firmness, hair, healing |
| BPC-157 | 10 mg | 14% | Tendon, gut, and tissue healing |
| TB-500 | 10 mg | 14% | Muscle and tendon healing, usually with BPC-157 |
| KPV (KLOW only) | 10 mg | 12.5% of 80 mg | Gut and skin inflammation |
By weight the vial is a GHK-Cu vial. Whatever dose of blend is drawn, seven parts in ten are copper peptide.
- Forms
- Freeze-dried blend vials of 70 mg (GLOW) and 80 mg (KLOW) from research vendors, reconstituted by the buyer and injected subcutaneously
- Price as sold
- About $100 to $150 for a GLOW vial and $95 to $160 for KLOW, roughly a month of the common protocol
- Status
- No approval, no compounding pathway, no human study of the combination. Each ingredient's own status is in section 05.
- Anti-doping
- BPC-157 and TB-500 are prohibited by WADA at all times; a GLOW injection is two banned substances
A blend is a decision made for you
Three peptides in one vial means one ratio, one dose, one schedule, and one reaction you cannot trace to an ingredient. Even a buyer who believes in all three would do better with three vials. The blend exists because it sells, not because anyone found the ratio.
Three ingredients, three evidence records, and a fourth in KLOW. Each has its own title in this series or an entry in the field guide; the summary here is what matters for the blend.
| Ingredient | Best human evidence | For injection | Grade |
|---|---|---|---|
| GHK-Cu | Small cosmetic studies of creams: firmer skin, fewer fine lines over 12 weeks | None. No human trial of injected GHK-Cu; FDA safety statement on record | C topical, D injected |
| BPC-157 | Three small uncontrolled human reports totaling about 30 people; hundreds of rat studies from one laboratory | Those three reports; no controlled trial | C |
| TB-500 | None for the fragment. The full thymosin beta-4 protein has small trials for venous ulcers and eye surface disease, with mixed results and one failed Phase 3 | None | D |
| KPV (KLOW) | None. Mouse colitis models and cell studies | None | D |
The combination: no study, no case series, no measurement in anyone. Every claim for GLOW is a claim for one ingredient, borrowed.
The strongest ingredient is the one you do not need to inject
GHK-Cu carries the only evidence in the vial, and all of it comes from creams applied to the skin. Injecting it to reach the skin is an untested detour. The two healing peptides are the same pair the field guide reviews as the Wolverine stack, with the same verdict: proposed to work by the same mechanism, never tested together.
A rational combination has three properties: each part has evidence on its own, the parts act by different mechanisms so they add rather than overlap, and the pair has been tested together at the ratio sold. Approved combination drugs meet all three. GLOW meets none.
| Test | GLOW |
|---|---|
| Each part works alone in humans | One part has cosmetic evidence, by a different route. The other two have none that is controlled |
| The parts act by different mechanisms | All three are sold on the same story: new blood-vessel growth and cell migration into tissue. They overlap rather than add |
| The combination was tested at this ratio | Never. The 50:10:10 ratio is a manufacturing convenience |
| Stability of the mixture | Untested. Three peptides with different chemistries, one of them carrying copper, freeze-dried together and reconstituted for a month of use |
The practical consequence is on the syringe. A dose of blend is a dose of the mixture, so the buyer cannot raise one ingredient without raising the others, cannot drop one that causes a reaction, and cannot tell which of three syntheses' impurities produced a red, swollen injection site. That is the blend-vial problem, and GLOW is its clearest case.
| Protocol | Instruction | What is known |
|---|---|---|
| Vendor standard | 70 mg vial with 3 mL of water; 10 units (2.33 mg of blend) once daily, subcutaneous, for 4 to 8 weeks | No human study; the dose is the one that makes a vial last a month |
| Low-dose variant | 500 mcg to 1 mg of blend daily | Cuts the healing peptides to a fraction of the doses their own sellers recommend |
| KLOW | 80 mg vial with 3 mL of water; 10 units (2.67 mg of blend) once daily, subcutaneous, for 4 to 8 weeks | Adds 10 mg KPV. At the same 3 mL the other three ingredients come out at exactly the GLOW amounts; a vial is 30 doses |
| Cycling | 4 to 8 weeks on, then a break | Custom; no data on whether breaks matter |
What the next tables are, and are not
They express the vendor protocol for the 70 mg vial as sold, so the arithmetic can be checked, and they show what each ingredient receives at that dose. Nothing here has been tested in a human trial, none of the ingredients may lawfully be compounded, and a research-chemical blend's identity, ratio, and sterility are unverified.
- Vial
- 70 mg blend (50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500), as sold; identity, ratio, and quantity unverified
- Water added
- 3 mL bacteriostatic water, the vendors' own instruction; a 3 mL glass vial holds it
- Concentration
- 23.3 mg/mL of blend, which is 16.7 mg/mL GHK-Cu, 3.3 mg/mL BPC-157, and 3.3 mg/mL TB-500. One concentration for the whole course.
- Syringe
- 0.3 mL insulin syringe; the standard draw is 10 units
| Weeks | Daily dose | Draw | Units | Used per 4 weeks |
|---|---|---|---|---|
| 1–4 | 2.33 mg of blend | 0.1 mL | 10 | 65 mg (about 1 vial) |
| 5–8 | 2.33 mg of blend, or stop | 0.1 mL | 10 | 65 mg (a second vial) |
| After 8 | Stop and reassess |
A 5-unit draw halves every figure below; at 500 mcg of blend, the dose is 2 units and cannot be measured.
What each draw looks like · 0.5 mL (50-unit) U-100 insulin syringe
The plunger tip sits on the line for the dose. Units are marks on a U-100 syringe: 100 units is 1 mL. The picture assumes the concentration in the table above; a different amount of water changes every line.
- KLOW vial
- 80 mg blend (50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, 10 mg KPV), as sold; identity, ratio, and quantity unverified
- Water added
- 3 mL bacteriostatic water, the same as GLOW, so the draw does not change between the two vials
- Concentration
- 26.7 mg/mL of blend, which is 16.7 mg/mL GHK-Cu and 3.3 mg/mL each of BPC-157, TB-500, and KPV. One concentration for the whole course.
- Syringe
- 0.3 mL insulin syringe; the standard draw is 10 units
- How long a vial lasts
- 3 mL is 30 draws of 10 units: 30 days of daily dosing on paper, 28 or 29 in practice once the liquid lost in each needle is counted. That matches the 4 weeks a reconstituted vial is conventionally kept.
| Weeks | Daily dose | Draw | Units | Used per 4 weeks |
|---|---|---|---|---|
| 1–4 | 2.67 mg of blend | 0.1 mL | 10 | 75 mg (1 vial, with two doses to spare) |
| 5–8 | 2.67 mg of blend, or stop | 0.1 mL | 10 | 75 mg (a second vial) |
| After 8 | Stop and reassess |
A 5-unit draw halves every ingredient and stretches the vial to 60 draws, but not to 60 days: no one has tested a reconstituted four-peptide blend past any date, and the convention for bacteriostatic water is about 4 weeks. At half dose, half the vial is discarded.
What each draw looks like · 0.5 mL (50-unit) U-100 insulin syringe
The plunger tip sits on the line for the dose. Units are marks on a U-100 syringe: 100 units is 1 mL. The picture assumes the concentration in the table above; a different amount of water changes every line.
| Ingredient | Per 10-unit dose | Sold alone at | Share |
|---|---|---|---|
| GHK-Cu | 1.67 mg (about 0.23 mg copper) | 1 to 2 mg daily | A full dose |
| BPC-157 | 333 mcg | 250 to 500 mcg daily | A full dose |
| TB-500 | 333 mcg daily (2.3 mg a week) | 2 to 2.5 mg twice weekly, then weekly | Half to a quarter |
| KPV (KLOW only) | 333 mcg | 200 to 500 mcg | A full dose |
At the vendor's 10-unit dose the arithmetic is more honest than the low-dose variant: the blend delivers ordinary doses of GHK-Cu and BPC-157 and a reduced dose of TB-500. That does not make the combination tested. It makes it three untested injections in one. KLOW changes the blend figure (2.67 mg against 2.33 mg) and nothing else: the fourth peptide is added on top, not carved out of the other three.
- The vendors' own protocol quietly doubles as a copper protocol: 1.67 mg of GHK-Cu a day is the clinic's GHK-Cu dose, so a GLOW user is running a full injected copper-peptide course whether they wanted one or not.
- The reconstituted vial is blue, from the copper. A GLOW vial that mixes clear is missing its main ingredient.
- There is no way to taper one ingredient. A buyer who wants to keep BPC-157 and drop the copper peptide has to buy BPC-157.
No regulator has ever looked at GLOW, because there is nothing to look at: a blend of unapproved substances has no sponsor, no application, and no route to a pharmacy. What FDA has looked at is each ingredient, and the answers differ.
| Ingredient | Status | What changed in 2026 |
|---|---|---|
| GHK-Cu (injected) | Unapproved drug; not compoundable; FDA safety statement on record | Left Category 2 in April when its nomination was withdrawn; committee review promised by February 2027 |
| BPC-157 | Unapproved; not compoundable | Left Category 2 in April; advisory committee voted 8 to 6 in July to recommend listing; rulemaking pending |
| TB-500 | Unapproved; not compoundable; WADA-prohibited | Same path as BPC-157: April removal, 8 to 6 vote in July, rulemaking pending |
| KPV | Unapproved; not compoundable | Same path: 8 to 6 vote in July, rulemaking pending |
An advisory vote is a recommendation. Until FDA finishes rulemaking, none of these is on the list, and even then each would be listed alone. Nothing in the process contemplates a 50:10:10 blend.
Even a best case leaves the blend outside the law
Suppose FDA lists BPC-157, TB-500, and KPV next year and later lists injectable GHK-Cu too. A pharmacy could then compound each on a prescription. It still could not sell GLOW: a compounded preparation is made to a prescriber's order for a patient, not to a vendor's recipe. The blend vial is a research-chemical product by nature, not by timing.
- FDA's stated concern for injectable GHK-Cu, immune reactions from aggregated peptide and impurities, applies with more force to a vial that also carries the impurities of two other syntheses.
- Vendors label the blend "research use only" and sell it with a dosing chart and bacteriostatic water. FDA's 2026 warning letters to peptide sellers cited exactly that combination as evidence of intent for human use.
- An athlete who injects GLOW has taken two prohibited substances. Contaminated-supplement defenses do not cover a product whose label lists them.
Reading a blend vial: the arithmetic in four parts11
A single-peptide vial has one concentration. A blend has one for the mixture and one for each ingredient, and the per-ingredient numbers are what matter, because that is what the body receives. Sellers quote the blend figure; buyers should compute the rest.
ingredient per dose = blend dose × (ingredient mg ÷ vial mg)
In GLOW, GHK-Cu is 50 of 70 mg, so a 2.33 mg blend dose carries 1.67 mg of it; BPC-157 and TB-500 are 10 of 70 each, so 0.33 mg apiece. Units come from the blend concentration: 70 mg in 3 mL is 23.3 mg/mL, and 2.33 mg is 0.1 mL, or 10 units.
| Draw | Blend | GHK-Cu | BPC-157 | TB-500 |
|---|---|---|---|---|
| 2 units (not measurable) | 0.47 mg | 0.33 mg | 67 mcg | 67 mcg |
| 5 units | 1.17 mg | 0.83 mg | 167 mcg | 167 mcg |
| 10 units | 2.33 mg | 1.67 mg | 333 mcg | 333 mcg |
| 20 units | 4.67 mg | 3.33 mg | 667 mcg | 667 mcg |
Reconstituted blends have no tested beyond-use date; refrigerate and assume degradation within weeks.
| Draw | Blend | GHK-Cu | BPC-157 | TB-500 | KPV |
|---|---|---|---|---|---|
| 5 units | 1.33 mg | 0.83 mg | 167 mcg | 167 mcg | 167 mcg |
| 10 units | 2.67 mg | 1.67 mg | 333 mcg | 333 mcg | 333 mcg |
| 20 units | 5.33 mg | 3.33 mg | 667 mcg | 667 mcg | 667 mcg |
30 draws of 10 units per vial. If a seller's KLOW instructions use a different water volume, every line changes: at 4 mL the concentration is 20 mg/mL and 10 units is 2 mg of blend.
Nothing is known about the safety of the combination because it has never been studied. What is known about each ingredient adds up, and the blend adds a problem of its own: a reaction cannot be attributed.
- Reported
- Injection-site pain, redness, and swelling; flushing; fatigue; light-headedness. Community reports for the blend and for GHK-Cu alone, uncounted.
- Attribution
- With three peptides in one syringe, a rash, a swollen site, or a systemic reaction cannot be traced to its cause, and the only remedy is to stop everything.
- Shared mechanism
- All three ingredients are sold on promoting new blood-vessel growth and cell migration, the programs tumors depend on. None has been studied in anyone with cancer or a cancer history, and the blend stacks the concern three times.
- Copper
- About 0.23 mg per 10-unit dose, a quarter of the daily dietary allowance; not a plausible overload, but unmeasured by injection. See the GHK-Cu guide.
- Product
- FDA's concern for injected GHK-Cu: aggregation, impurities, immune reactions. A blend carries three syntheses' impurities and an untested mixture chemistry.
- Sterility
- Research-chemical vials are not certified sterile or endotoxin-free for injection, and a blend vial is opened daily for a month.
- Unknown
- Pregnancy, copper disorders, use with other injected peptides, and anything beyond eight weeks.
- Athletes
- Two prohibited substances per injection; a positive test at any time.
- Which of the three ingredients am I actually buying this for? Would that one, alone, at its own dose, do the job?
- What is the evidence for that ingredient by injection? (For GHK-Cu, none; for TB-500, none; for BPC-157, three small uncontrolled reports.)
- What does each ingredient receive per dose at the water volume I am using? Is the TB-500 a fraction of what it is sold at alone?
- If I get a reaction, how will I know which peptide caused it?
- Can the seller show a certificate of analysis for this lot with identity, ratio, and sterility, not purity alone?
- Do I have a cancer history, a copper disorder, or am I subject to anti-doping rules?
- What is being measured to decide whether it works, and by when?
What does have evidence for what GLOW is sold for
For skin: daily sunscreen, tretinoin, and copper peptide or vitamin C serums applied to the skin. For tendon and ligament injury: progressive loading under a physical therapist, sleep, protein, and time. For gut inflammation: a gastroenterologist and the approved drugs, which have outcome trials. Every one of these has more human evidence than the vial.
Latest
Developments since this edition, newest first. Items here are dated and sourced; they update the guide without re-editing it.
NPR: injected GHK-Cu, the largest ingredient in the vial, has no published human studies
NPR reported that the move from copper-peptide creams to GHK-Cu injections has no published human safety or efficacy data behind it. A Seattle-area nurse practitioner described injection-site infections and patients with raised liver enzymes and copper levels after self-injecting; these are clinic observations, not a published case series.
UCLA review of 565 studies finds almost no human evidence for six popular recovery peptides
Orthopedic researchers reviewed 565 studies of BPC-157, TB-500, CJC-1295, ipamorelin, MK-677, and GHK-Cu for muscle, tendon, and joint use (American Journal of Sports Medicine, 2026). More than two-thirds were animal-only, and the authors found essentially no studies showing a significant clinical benefit for musculoskeletal conditions.
Six peptides recommended; none compoundable until a final rule
The pharmacists' association reports the committee recommended BPC-157, KPV, TB-500, MOTS-c, epitalon, and Semax, that the votes are nonbinding, and that pharmacies may not compound any of them until rulemaking is complete. GHK-Cu, the bulk of a GLOW vial, was not reviewed.
Tallies confirmed: BPC-157, KPV, and TB-500 each 8 to 6 with one abstention
A law-firm summary gives the full tallies and notes rulemaking may extend into 2027 or beyond. GHK-Cu is deferred to a meeting before the end of February 2027, so even after any rule the three- and four-peptide blends could not be compounded as sold.
FDA scientists objected to the peptide recommendations
FDA staff told the committee the compounds lack universally accepted chemical definitions, which makes safety and effectiveness hard to evaluate; the committee voted 8 to 6 for BPC-157, KPV, and TB-500 anyway.
Panel narrowly backs BPC-157, KPV, TB-500, and MOTS-c
Coverage framed the day-one votes as a win for the HHS secretary's push on peptides and noted the recommendations do not bind FDA, though the agency rarely overrules its panels.
References
- 1.Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- 2.Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals. 2025;18(2):185. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859134/
- 3.Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. https://pubmed.ncbi.nlm.nih.gov/34324435/
- 4.Guarnera G, et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci. 2007;1112:407-412. https://pubmed.ncbi.nlm.nih.gov/17495250/
- 5.Sosne G, et al. 0.1% RGN-259 (thymosin beta-4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Int J Mol Sci. 2023;24(1):558. https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/
- 6.Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- 7.U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee, July 23-24, 2026 (BPC-157, TB-500, KPV, MOTS-c, epitalon, semax recommended; emideltide not). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 8.U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (April 2026 update: withdrawn nominations including GHK-Cu, BPC-157, TB-500, and KPV). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
- 9.U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (GHK-Cu, injectable routes). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- 10.World Anti-Doping Agency. The Prohibited List 2026: S0 (non-approved substances, including BPC-157) and S2 (including TB-500). https://www.wada-ama.org/en/prohibited-list
- 11.Representative GLOW (70 mg) and KLOW (80 mg) blend listings and reconstitution instructions from research-chemical vendors, as sold September 2026 (3 mL reconstitution; 10 units daily). https://peptidedosages.com/peptide-blend-dosages/glow-70-mg-vial-dosage-protocol/
- 12.Vendor comparison of the Wolverine, GLOW, and KLOW blends, with stated vial compositions and protocols (PeRx Peptides, 2026). https://www.perxpeptides.com/blog/glow-vs-klow-vs-wolverine-stack